Disseminated coccidioidomycosis (DCM), often a severe and refractory disease leading to poor outcomes, is a risk for people with certain primary immunodeficiencies (PID). Several DCM-associated PID (STAT4, STAT3, IFNγ, and Dectin-1) are modeled in mice. To determine if vaccination could provide these mice protection, mice with mutations in Stat4, Stat3, Ifngr1, Clec7a (Dectin-1), and Rag-1 (T- and B-cell deficient) knockout (KO) mice were vaccinated with the live, avirulent, Δcps1 vaccine strain and subsequently challenged intranasally with pathogenic Coccidioides posadasii Silveira strain. Two weeks post-infection, vaccinated mice of all strains except Rag-1 KO had significantly reduced lung and spleen fungal burdens (p<0.05) compared to unvaccinated control mice. Splenic dissemination was prevented in most vaccinated immunodeficient mice while all unvaccinated B6 mice and the Rag-1 KO mice displayed disseminated disease. The mitigation of DCM by Δcps1 vaccination in these mice suggests that it could also benefit humans with immunogenetic risks of severe disease.
CITATION STYLE
Powell, D. A., Hsu, A. P., Butkiewicz, C. D., Trinh, H. T., Frelinger, J. A., Holland, S. M., … Shubitz, L. F. (2022). Vaccine Protection of Mice With Primary Immunodeficiencies Against Disseminated Coccidioidomycosis. Frontiers in Cellular and Infection Microbiology, 11. https://doi.org/10.3389/fcimb.2021.790488
Mendeley helps you to discover research relevant for your work.